Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2012

View Archived Issues

Omeros reports data from second pivotal phase III OMS-302 trial

Phase III study of BMN-110 meets primary endpoint

Sanofi and Regeneron begin enrollment in phase III ODYSSEY OUTCOMES trial

Ventrus Biosciences receives FDA feedback for VEN-307 program

Significantly elevated IL-8 levels detected in patients with PAP

Superior model of colorectal cancer devised

First clinical study of RaQualia's novel 5-HT4 partial agonist completed

Merck & Co. to initiate phase II trials of MK-5172

Newron signs amended agreement to acquire NeuroNova

UCB updates progress of third quarter 2012

Novel ACAT inhibitors disclosed by Pierre Fabre Medicament

Antihypercholesterolemic activity of RN-316 confirmed in early clinical studies

GlaxoSmithKline divulges new mTOR inhibitors

Dainippon Sumitomo Pharma highlights progress of second quarter of fiscal 2012

Karo Bio designs novel estrogen receptor-beta ligands

Biomarkers of acute kidney injury in critical care patients compared

New beta-secretase inhibitors presented by Roche and Siena Biotech

New JNK1 inhibitors revealed by Roche

Spanish group synthesizes new histone deacetylase inhibitors

Watson completes acquisition of Actavis

Daiichi Sankyo gives update on activities of second quarter of fiscal 2012

Long-term clinical remission and mucosal healing demonstrated with golimumab

Zafgen advances obesity therapy to phase IIa development

Isotechnika Pharma's NICAMs show antiviral activity in initial screening

Enrollment completed in phase III study of custirsen in advanced prostate cancer

FDA designates dalbavancin as a QIDP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...